LLY Lilly(Eli) Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NYSE: LLY
  4. Earnings
Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 99

EPS in 2026 (TTM): $28.19

Last Report Period Date: Mar 31, 2026

Currently, LLY's trailing twelve months (TTM) EPS stands at $28.19, according to the most recent financial reports. In 2025, LLY reported a per-share earnings of $23, which represents an increase compared to the EPS of $11.76 recorded in 2024. LLY recorded an EPS of $8.27 for the quarterly period ending on Mar 31, 2026.

LLY earnings history

Historical annual and quarterly earnings per share (EPS) data for Lilly(Eli)
EPS (TTM)
$28.19
EPS Growth YoY (Quarterly)
169.4%
EPS (Quarterly)
$8.27
EPS Growth (Quarterly)
11.8%

In 2025, Lilly(Eli)'s EPS was $23, an increase of 95.6% from $11.76 in 2024. For the quarter ending Mar 31, 2026, the EPS was $8.27, reflecting a 169.4% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of March 2026 is $28.19. In 2024, the annual EPS was $11.76, showing an increase of 102.1% compared to 2023.

LLY earnings chart

LLY EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
169.4%
EPS growth YoY
95.6%
EPS growth 3Y avg
49.2%
EPS growth 5Y avg
27.5%

Over the past 12 months, Lilly(Eli) has recorded an earnings per share growth of 169.4% (YoY, quarterly). Over a three-year span, the company had an average EPS annual growth rate of 49.2% per year. Over the last five years, the company had an average annual EPS growth of 27.5%. When assessed over a ten-year period, LLY's average EPS annual growth was 26.1%.

LLY Earnings Waterfall

Breakdown of revenue, profit and net income for Lilly(Eli)

LLY Earnings vs Peers

What are the earnings of LLY compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 14.65 178.7% 5.3% N/A
PFE Pfizer Inc 19.32 -3.5% -37.4% -3.7%
AZN Astrazeneca plc 23.24 45.4% 46% 22%
NVS Novartis AG 23.34 21.8% 31.2% 15.2%
AMGN AMGEN Inc 26.74 88.1% 5.6% 2.9%
JNJ Johnson & Johnson 29.14 90.6% 17.7% 14.8%
MRK Merck & Co Inc 36.4 8% 8.4% 21.2%
LLY Lilly(Eli) & Company 40.5 95.6% 49.2% 27.5%
ABBV Abbvie Inc 123.78 -1.3% -29.1% -2.8%

All data is based on quarterly TTM periods, unless otherwise specified.